Arca
Skip to content
Tools
Tools

NS3, NS4A: Hepatitis C virus serine protease, NS3/NS4A

Complex in Hepatitis C virus that 17 drugs act on.

  • Drugs that act on it: 17
  • Approved: 8
  • In phases 1 to 3: 9
  • Sponsors: 11

Who is on it, and how far along

Every drug ChEMBL records acting on NS3, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 17

Approved8

  • Glecaprevir
  • Voxilaprevir
  • Paritaprevir
  • Asunaprevir
  • Boceprevir
  • Grazoprevir anhydrous
  • Simeprevir
  • Telaprevir

Phase 35

  • Danoprevir
  • Faldaprevir
  • Furaprevir
  • Narlaprevir
  • Vaniprevir

Phase 24

  • Ciluprevir
  • GS-9256
  • Sovaprevir
  • Vedroprevir

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Hepatitis C virus serine protease, NS3/NS4A inhibitor.
    GlecaprevirApprovedAbbVieSmall moleculeInhibitor4
    VoxilaprevirApprovedGilead SciencesSmall moleculeInhibitor4
    ParitaprevirApprovedAbbVieSmall moleculeInhibitor1
    AsunaprevirApprovedBristol-Myers SquibbSmall moleculeInhibitor0
    BoceprevirApprovedMerck & Co. (MSD)Small moleculeInhibitor0
    Grazoprevir anhydrousApprovedMerck & Co. (MSD)Small moleculeInhibitor0
    SimeprevirBoxed warningApprovedJohnson & JohnsonSmall moleculeInhibitor0
    TelaprevirBoxed warningApprovedVertex PharmaceuticalsSmall moleculeInhibitor0
    DanoprevirPhase 3Ascletis Pharmaceuticals Co., Ltd.Small moleculeInhibitor0
    FaldaprevirPhase 3Boehringer Ingelheim PharmaceuticalsSmall moleculeInhibitor0
    FuraprevirPhase 3TaiGen Biotechnology Co., Ltd.Small moleculeInhibitor0
    NarlaprevirPhase 3R-PharmSmall moleculeInhibitor0
    VaniprevirPhase 3Merck & Co. (MSD)Small moleculeInhibitor0
    CiluprevirPhase 2—Small moleculeInhibitor0
    GS-9256Phase 2Gilead SciencesSmall moleculeInhibitor0
    SovaprevirPhase 2AstraZeneca PharmaceuticalsSmall moleculeInhibitor0
    VedroprevirPhase 2Gilead SciencesSmall moleculeInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 9 in all, from ClinicalTrials.gov.
    Treatment of CKD Patients With HCVParitaprevirPhase 2 / Phase 3Not yet recruitingTanta UniversityAug 18, 2026
    Sofosbuvir/Velpatasvir/Voxilaprevir Salvage Therapy in Hepatitis C Patients Who Relapsed After DAA TreatmentVoxilaprevir—Active, not recruitingXiangya Hospital of Central South UniversityMay 4, 2026
    Combating Related Epidemics in HCVVoxilaprevirPhase 4Not yet recruitingDuke UniversityApr 30, 2026
    Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World DataGlecaprevir—RecruitingAbbVieFeb 19, 2026
    Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard StrategyVoxilaprevirPhase 4Not yet recruitingANRS, Emerging Infectious DiseasesAug 1, 2025
    Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIVGlecaprevirPhase 1 / Phase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)Jun 27, 2025
    Feasibility and Acceptability of HCV Treatment in PregnancyGlecaprevir—RecruitingWashington University School of MedicineApr 16, 2024
    The Efficacy of Vosevi in Treating DAA-experienced PatientsVoxilaprevir—RecruitingThe Third Affiliated Hospital of Guangzhou Medical UniversityDec 22, 2023
    Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvirGlecaprevirPhase 4RecruitingKirby InstituteFeb 27, 2019

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2095231, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.